Lamotrigine (LTG) in Treatment of Juvenile Myoclonic Epilepsy (JME).
Abstract number :
F.01
Submission category :
Year :
2001
Submission ID :
2817
Source :
www.aesnet.org
Presentation date :
12/1/2001 12:00:00 AM
Published date :
Dec 1, 2001, 06:00 AM
Authors :
M.A. Nadkarni, MD, Neuroscience, NJ Neuroscience Institute, Edison, NJ
RATIONALE: LTG is FDA approved for control of partial onset Epilepsy.It has been reported to possibly worsen infantile myoclonic Epilepsy. Limited data is available for its use in Idiopathic primary generalized epilepsy. This study assessed efficacy of LTG in patients with JME.
METHODS: Four female patients with diagnosis of JME were initiated on LTG regimen. Three patients were intolerant to Sodium Valproate(VPA);therefore LTG treatment was considered as possible alternative. One patient was started on LTG de novo. Age range varied from 15- 32 years. Over a period of 3-4 months all patients were converted to LTG monotherapy.
RESULTS: All four patients are seizure free on LTG monotherapy with follow up period ranging from 16 to 22 months. LTG dose ranged from 100-450 mg/day. LTG serum levels varied from 1.4-4.6 mg/liter. One patient became pregnant while on montherapy and delivered a healthy baby. Interestingly, in all patients, sleep deprived routine EEG showed normalization. LTG was well tolerated by all four patients.
CONCLUSIONS: LTG as monotherapy appears to be effective and well tolerated in treatment of JME. LTG should be considered as a valid alternative to standard treatment by VPA. Larger studies assessing this finding should be considered.